MWNA
KPTI icon

Marshall Wace North America’s Karyopharm Therapeutics KPTI Stock Holding History

Marshall Wace North America’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-4,459
Closed -$644K – 1444
2019
Q3 		$644K Buy
+4,459
New +$605K ﹤0.01% 767
2019
Q2 		– Sell
-7,572
Closed -$663K – 1377
2019
Q1 		$663K Buy
+7,572
New +$839K ﹤0.01% 742
2018
Q4 		– Sell
-3,329
Closed -$851K – 1563
2018
Q3 		$851K Buy
+3,329
New +$920K 0.01% 628
2018
Q1 		– Sell
-676
Closed -$97K – 1566
2017
Q4 		$97K Buy
+676
New +$109K ﹤0.01% 1317

Other funds holding KPTI

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace North America's KPTI Position: Q4 2019 in Review

Marshall Wace North America sold out of Karyopharm Therapeutics (KPTI) in Q4 2019, closing a stake of 4,459 shares — an estimated $644K sold.

Marshall Wace North America first reported a position in KPTI in Q4 2017 and held it in 4 quarters. The position peaked at $851K in Q3 2018. 146 funds tracked by Wall St. Rank hold KPTI as of Q4 2019.

  • Marshall Wace North America reported no remaining Karyopharm Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Marshall Wace North America sold 4,459 Karyopharm Therapeutics shares in Q4 2019, an estimated $644K.
  • Marshall Wace North America first reported a position in Karyopharm Therapeutics in Q4 2017 and held it in 4 quarters.
  • Marshall Wace North America's Karyopharm Therapeutics position peaked at $851K in Q3 2018.
  • 146 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2019.

Based on Marshall Wace North America's 13F filing for Q4 2019, filed 14 Feb 2020.